Why Farbe Firma is the Top Manufacturer of Dobutamine HCL Injection
- Maulik Sudani
- 2 days ago
- 8 min read
Last Updated: June 20, 2026
TL;DR: Dobutamine HCL Injection — a sterile, clear, colourless to faintly straw-coloured aqueous solution of dobutamine hydrochloride, a synthetic catecholamine and predominantly beta-1 adrenergic agonist inotrope, supplied commonly as a 12.5 mg/mL concentrate in a 250 mg/20 mL vial that is diluted before a closely titrated continuous intravenous infusion — is a frontline intensive-care agent for short-term inotropic support in acute decompensated heart failure, cardiogenic shock and low-cardiac-output states, and as the pharmacological agent in dobutamine stress echocardiography. Because the patient is critically ill, the drug is titrated by infusion pump under continuous haemodynamic monitoring and dobutamine is an oxidation- and light-sensitive catecholamine, each vial must deliver an exact, sterile, particulate-free dose at the labelled concentration, with the assay, the oxidative and related-substance profile, antioxidant and pH control, an inert-gas headspace, fill volume, low particulate and endotoxin, a validated sterilisation route, light-protective packaging and verified container-closure integrity all mattering to safety and shelf life. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Dobutamine HCL Injection at our Gujarat, India facility and supplies it to intensive-care, cardiology, anaesthesia and hospital-pharmacy services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Synthetic catecholamine / predominantly beta-1 adrenergic agonist inotrope (dobutamine hydrochloride) — Dobutamine HCL Injection is diluted and given as a closely titrated continuous intravenous infusion under continuous haemodynamic monitoring for short-term inotropic support in acute decompensated heart failure, cardiogenic shock and low-cardiac-output states, and for dobutamine stress echocardiography, where smooth, precise, reproducible dosing is essential.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, dedicated light-protected and nitrogen-purged compounding and vial filling lines, control of the stability-indicating assay, the oxidative and related-substance profile, antioxidant content, solution pH, fill volume, particulate and endotoxin, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, sterilisation and container-closure data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile-solution concentrate vial contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Dobutamine HCL Injection Demands a Premium Manufacturer
Dobutamine HCL Injection holds a critical, time-sensitive place in intensive-care units, coronary-care units, cardiology services and cardiac-surgery recovery across every market. It is the inotrope clinicians reach for when a failing heart needs short-term support — to raise cardiac output and tissue perfusion in acute decompensated heart failure, in cardiogenic shock and in the low-output state that can follow cardiac surgery — and it is also the pharmacological stress agent used in dobutamine stress echocardiography when a patient cannot exercise. As a predominantly beta-1 adrenergic agonist given as a titratable continuous infusion, dobutamine lets a treating team dial inotropic support to the patient's haemodynamics in real time. In each of these settings the dose delivered from each vial must be exact, sterile, particulate-free and reliably the same from unit to unit, because safe titration in a critically ill patient on an infusion pump depends on a precise, reproducible concentration given without delay.
That clinical reality places real demands on the manufacturer. Dobutamine HCL Injection is a concentrate — commonly 12.5 mg/mL in a 250 mg/20 mL vial — that is diluted before continuous infusion, so the assay must be exact, the impurity and degradation profile must stay within tight limits, and the solution pH must be held in the controlled, slightly acidic range that keeps dobutamine soluble and stable. Critically, dobutamine is a catecholamine, a chemical class that is intrinsically oxidation- and light-sensitive: exposed to oxygen or light it can oxidise and develop a slight pink discolouration, a visible signal of degradation that a manufacturer must engineer out. To defend it, the manufacturer must compound at a controlled, slightly acidic pH, add an antioxidant such as sodium metabisulfite, purge and blanket the solution and headspace with an inert gas to exclude oxygen, run a validated ICH Q1B photostability programme and package to protect the product from light. The solution must be free of visible and sub-visible particulates and low in endotoxin, the sulfite content declared on the label for sensitive patients, the fill volume accurate so each vial delivers the labelled content, and the right sterilisation route — terminal moist-heat where the formulation and container qualify, otherwise full aseptic processing — selected and validated. Choosing a Dobutamine HCL Injection manufacturer that treats the stability-indicating assay, oxidation and photostability control, antioxidant and pH control, fill-volume accuracy, particulate and endotoxin control and container-closure integrity as core engineering disciplines is what protects the patient at the point of care.
What Sets a World-Class Dobutamine HCL Injection Manufacturer Apart
A world-class manufacturer of Dobutamine HCL Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay of dobutamine hydrochloride with related-substance and oxidative-degradation control by validated HPLC that a critical-care inotrope demands, a robust, validated, light-protected and oxygen-excluding sterilisation and fill process that protects sterility, colour, pH and clarity in an oxidation-sensitive catecholamine concentrate, and tender-ready dossier support for a high-volume hospital-formulary critical-care product procured through pharmacy and ministry-of-health channels. It starts with the active — pharmacopoeial-grade dobutamine hydrochloride sourced from qualified, audited API makers, with full assay, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production.
Compounding and filling then have to defend the assay, the colour, the pH and the oxidative stability of the concentrate. The bulk solution is compounded in water-for-injection at the controlled, slightly acidic pH that keeps dobutamine hydrochloride soluble and stable, with an antioxidant such as sodium metabisulfite, under a continuous inert-gas (nitrogen) purge that strips dissolved oxygen, then sterile-filtered through 0.22 µm membrane and filled into vials under ISO Class 5 conditions with a nitrogen headspace overlay and the workflow shielded from light, with the validated sterilisation route — terminal moist-heat where the formulation and container qualify, otherwise full aseptic processing — locked in the master batch record. Filled units are 100 % inspected for fill, seal, clarity, colour and particulate defects; in-process and release testing confirm the assay of dobutamine hydrochloride by validated HPLC, the related-substance and oxidative-degradation profile, antioxidant content, solution pH, deliverable (fill) volume, visible and sub-visible particulate matter, and that endotoxin is held well within limits so the solution is safe for intravenous infusion. Because dobutamine is oxidation- and light-sensitive, assay accuracy, oxidation control, photostability, light-protective packaging and container-closure integrity are validated together so the assay, colour and clarity stay within specification across shelf life.
Quality Systems Behind Every Dobutamine HCL Injection
Every Farbe Firma Dobutamine HCL Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of dobutamine hydrochloride against pharmacopoeial reference standards, control of related substances and oxidative-degradation products by HPLC, antioxidant (sulfite) content, solution pH, clarity and colour of the solution, deliverable (fill) volume, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the vial format. Certificates of analysis are issued with full traceability back to each API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated sterilisation and depyrogenation equipment, validated light-protected, nitrogen-blanketed filling lines with 100 % inspection, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because dobutamine hydrochloride injection is an oxidation- and light-sensitive intravenous critical-care inotrope and the assay, colour, oxidative profile, antioxidant content, pH, particulate and endotoxin burden drive both efficacy and safety, we treat the stability-indicating assay, the oxidative-degradation profile, the antioxidant content, the solution pH and the deliverable volume as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under both long-term (25 °C / 60 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions, with a full ICH Q1B photostability challenge, so the assay, colour, clarity and pH stay within specification across the labelled shelf life.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Dobutamine HCL Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a broad critical-care, cardiology and emergency small-volume parenteral portfolio. For Dobutamine HCL Injection specifically, we supply the 12.5 mg/mL concentrate in the 250 mg/20 mL vial presentation under WHO-GMP conditions, with country-specific strengths, fill configurations, light-protective tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the stability-indicating-assay, oxidative-degradation, antioxidant, pH, sterilisation and container-closure data package — ready to hand for registration and tender qualification.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, sterilisation and container-closure reports, translated package inserts and artwork — including dilution-before-infusion, protect-from-light handling and sulfite-content warnings — for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Dobutamine HCL Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the compounding and filling suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API sourcing, stability-indicating assay development, related-substance and oxidative-degradation control, antioxidant and pH formulation design, inert-gas and light-protective process and packaging engineering, the choice between terminal sterilisation and aseptic filling, fill-volume and deliverable-dose accuracy, particulate and endotoxin control, container-closure integrity and shelf-life choices in real detail. For a critical-care inotrope where assay accuracy, oxidation and photostability control and dose precision directly govern both efficacy and safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Dobutamine HCL Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Dobutamine HCL Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, validated water-for-injection systems, dedicated light-protected and nitrogen-purged compounding and vial filling lines, validated sterilisation, 100 % inspection and continuous environmental monitoring.
Which strengths and pack sizes of Dobutamine HCL Injection do you supply?
Our standard presentation is the 12.5 mg/mL concentrate of dobutamine hydrochloride in a 250 mg/20 mL vial, diluted before slow continuous intravenous infusion. Custom strengths, fill configurations, vial formats, light-protective tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Dobutamine HCL Injection mainly used for?
Dobutamine HCL Injection is used for short-term inotropic support in acute decompensated heart failure, cardiogenic shock and low-cardiac-output states, and as the pharmacological agent in dobutamine stress echocardiography. It is a predominantly beta-1 adrenergic catecholamine given as a closely titrated continuous intravenous infusion under haemodynamic monitoring; Farbe Firma verifies the assay, oxidative profile, antioxidant content, pH, deliverable volume, particulate matter and endotoxin at release so each vial delivers a precise, reproducible dose.
Can Farbe Firma support country-specific registrations for Dobutamine HCL Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, sterilisation and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Dobutamine HCL Injection contract manufacturing?
MOQs vary by strength, vial size, sterilisation route, light-protective packaging, label complexity and dossier requirements. For our critical-care small-volume parenteral presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments